Advisory Services Network’s Dyne Therapeutics DYN Stock Holding History

Advisory Services Network’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$526	Buy	+29	New	+$500	﹤0.01%	4415
2025 Q4	–	Sell	-14	Closed	-$177	–	2478
2025 Q3	$177	Buy	+14	New	+$160	﹤0.01%	4237

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Advisory Services Network's DYN Position: Q1 2026 in Review

Advisory Services Network opened a new position in Dyne Therapeutics (DYN) in Q1 2026: 29 shares worth $526. The stake represents ﹤0.01% of the portfolio and ranks #4415 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in DYN as recently as Q3 2025.

Advisory Services Network first reported a position in DYN in Q3 2025 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Advisory Services Network held 29 shares of Dyne Therapeutics worth $526 as of Q1 2026.
Dyne Therapeutics was a new Advisory Services Network position in Q1 2026.
Dyne Therapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #4415 holding.
Advisory Services Network first reported a position in Dyne Therapeutics in Q3 2025 and has held it in 2 quarters since.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.